Effect of Citrus Juice and SLCO2B1 Genotype on the Pharmacokinetics of Montelukast

被引:54
作者
Mougey, E. B. [1 ]
Lang, J. E. [1 ]
Wen, X. [2 ]
Lima, J. J. [1 ]
机构
[1] Nemours Childrens Clin, Pharmacogenet Ctr, Jacksonville, FL 32207 USA
[2] Univ Florida, Dept Stat, Gainesville, FL 32611 USA
关键词
Absorption; anti-inflammatory agents - non-steroidal; asthma; genetic polymorphisms; genotype-phenotype association; grapefruit juice; hplc; human; in vivo; individualization; inflammation; montelukast; organic anion transport; pharmacodynamics; pharmacogenetics; pharmacokinetics; transporter; GRAPEFRUIT JUICE; P-GLYCOPROTEIN; CLINICAL-RESPONSE; FELODIPINE INTERACTION; PLASMA-CONCENTRATIONS; RECEPTOR ANTAGONIST; FRUIT JUICES; BIOAVAILABILITY; ASTHMA; PHARMACOGENETICS;
D O I
10.1177/0091270010374472
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Previously the authors found that a common polymorphism, rs12422149 (SLCO2B1{NM_007256.2}: c.935G > A), in the gene coding for OATP2B1, was associated with absorption of and response to montelukast in humans. In vitro studies showed that citrus juice could reduce the permeability of montelukast consistent with known inhibition of organic anion-transporting polypeptides. To study the clinical significance of c.935G > A, the authors conducted a single-dose, pharmacokinetic study of montelukast co-ingested with citrus juice. On average, coingestion with either orange juice or 4x concentrated grapefruit juice had a minimal effect on the area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(0 ->infinity)) of montelukast relative to co-ingestion with Gatorade control (n = 24). However when the data were stratified by genotype at c. 935 (G/G n = 21, A/G n = 5), a significant reduction in AUC(0 ->infinity) was detected with orange juice in G/G homozygotes (AUC(0 ->infinity), G/G, Gatorade = 2560 +/- 900 ng.h.mL(-1) vs AUC(0 ->infinity), G/G, orange juice = 2010 +/- 650 ng . h . mL-1, P =.032). Significantly, A/G heterozygotes showed reduced AUC(0 ->infinity) relative to G/G homozygotes, independent of treatment (AUC(0 ->infinity), G/G, combined treatments = 2310 +/- 820 ng.h.mL(-1) vs AUC(0 ->infinity), A/G, combined treatments = 1460 +/- 340 ng.h.mL(-1), P = 2.0 x 10(-5)) replicating previous observations.
引用
收藏
页码:751 / 760
页数:10
相关论文
共 52 条
[1]   Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT1 antagonist, pranlukast, in Japanese patients with moderate asthma [J].
Asano, K ;
Shiomi, T ;
Hasegawa, N ;
Nakamura, H ;
Kudo, H ;
Matsuzaki, T ;
Hakuno, H ;
Fukunaga, K ;
Suzuki, Y ;
Kanazawa, M ;
Yamaguchi, K .
PHARMACOGENETICS, 2002, 12 (07) :565-570
[2]   Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice [J].
Bailey, D. G. ;
Dresser, G. K. ;
Leake, B. F. ;
Kim, R. B. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (04) :495-502
[3]   GRAPEFRUIT JUICE FELODIPINE INTERACTION - MECHANISM, PREDICTABILITY, AND EFFECT OF NARINGIN [J].
BAILEY, DG ;
ARNOLD, JMO ;
MUNOZ, C ;
SPENCE, JD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (06) :637-642
[4]   Grapefruit juice felodipine interaction:: Effect of naringin and 6′,7′-dihydroxybergamottin in humans [J].
Bailey, DG ;
Kreeft, JH ;
Munoz, C ;
Freeman, DJ ;
Bend, JR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (03) :248-256
[5]  
Balani SK, 1997, DRUG METAB DISPOS, V25, P1282
[6]   Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine [J].
Banfield, C ;
Gupta, S ;
Marino, M ;
Lim, J ;
Affrime, M .
CLINICAL PHARMACOKINETICS, 2002, 41 (04) :311-318
[7]   The LightTyper™:: High-throughput genotyping using fluorescent melting curve analysis [J].
Bennett, CD ;
Campbell, MN ;
Cook, CJ ;
Eyre, DJ ;
Nay, LM ;
Nielsen, DR ;
Rasmussen, RP ;
Bernard, PS .
BIOTECHNIQUES, 2003, 34 (06) :1288-+
[8]   Asthma guidelines: A changing paradigm to improve asthma care [J].
Busse, WW ;
Lenfant, C ;
Lemanske, RF .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2002, 110 (05) :703-705
[9]   Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females [J].
Cheng, HY ;
Leff, JA ;
Amin, R ;
Gertz, BJ ;
DeSmet, M ;
Noonan, N ;
Rogers, JD ;
Malbecq, W ;
Meisner, D ;
Somers, G .
PHARMACEUTICAL RESEARCH, 1996, 13 (03) :445-448
[10]  
Cvetkovic M, 1999, DRUG METAB DISPOS, V27, P866